Brief Article
Copyright ©2010 Baishideng.
World J Gastroenterol. Apr 28, 2010; 16(16): 2017-2022
Published online Apr 28, 2010. doi: 10.3748/wjg.v16.i16.2017
Table 1 Clinical features of the two groups of patients at examination n (%)
Upper endoscopy finding
TotalP-value
Gastric ulcersDuodenal ulcers
Case numbers (prevalence)254 (56.6)194 (43.4)448 (100)
Age (yr)60.44 ± 15.2751.99 ± 16.240.0011
Gender
Male142 (55.8)110 (56.7)252 (56.2)0.8662
Female112 (44.1)84 (43.3)196 (43.8)
H. pylori
Positive110 (43.3)121 (62.4)231 (56.7)0.0012
Negative144 (56.7)73 (37.6)217 (43.3)
Smoking
Yes36 (14.2)31 (16.0)67 (15.8)0.5952
No218 (85.8)163 (84.0)381 (86.0)
Alcohol
Yes21 (8.3)22 (11.3)43 (9.6)0.2742
No233 (91.7)172 (88.7)405 (90.4)
Co-medications
Nil218 (85.8)187 (96.4)405 (90.4)0.0012
Aspirin19 (7.5)3 (1.5)22 (4.9)
NSAIDs17 (6.7)4 (2.1)21 (4.7)
Table 2 The impact of therapeutic efficacy according to H. pylori infection and ulcer location of patients n (%)
Therapeutic efficacy
TotalP-value
Ulcer healedUlcer unhealed
H. pylori
GU
Positive infections77 (70.6)32 (29.4)1090.661
Negative infections99 (68.3)46 (31.7)145
DU
Positive infections87 (71.9)34 (28.1)1210.505
Negative infections55 (75.3)18 (24.7)73
Medications
GU
Treat with PPI  131 (79.4)34 (20.6)1650.007
Treat with H2RA56 (62.9)33 (37.1)89
DU
Treat with PPI  115 (78.2)32 (21.8)1470.430
Treat with H2RA34 (72.3)13 (27.7)47
Table 3 The impact of therapeutic efficacy according to co-medications and ulcer location of patients n (%)
Co-medicationsTherapeutic efficacy
TotalP-value
Ulcer healedUlcer unhealed
None
Positive H. pylori infection159 (75.7)51 (24.3)2100.370a
Negative H. pylori infection140 (71.8)55 (28.2)195
ASP
Positive H. pylori infection8 (80)2 (20)100.195b
Negative H. pylori infection12 (100)012
NSAID
Positive H. pylori infection6 (60)4 (40)100.035b
Negative H. pylori infection11 (100)011